Antiplatelet agents in the perioperative period: Expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001 - Summary Statement

Canadian Journal of Anesthesia

Volumn 49, Issue 6, 2002, Pages

  Samama, Charles M ^a   Bastien, Olivier ^a   Forestier, François ^a   Denninger, Marie Hélène ^a   Isetta, Christian ^a   Juliard, Jean Michel ^a   Lasne, Dominque ^a   Leys, Didier ^a   Mismetti, Patrick ^a   Albaladejo, Pierre ^a   Amerenco, Pierre ^a   Carteaux, Jean Pierre ^a   Charpentier, François ^a   Daudenthun, Isabelle ^a   Dubé, Laurent ^a   Fernandez, Hervé ^a   French, Patrick ^a   Gaertner, Elisabeth ^a   Lacroix, Philippe ^a   Marret, Emmanuel ^a   Marzelle, Jean ^a   May, Marc Antoine ^a   Nguyen, Philippe ^a   Rosencher, Nadia ^a   more..

^a AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FLURBIPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; THROMBOXANE A2; TICLOPIDINE; TIROFIBAN; VON WILLEBRAND FACTOR;

ANESTHESIOLOGY; ANESTHESIST; ARTICLE; BINDING COMPETITION; BINDING SITE; BLEEDING; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DRUG EFFECT; DRUG WITHDRAWAL; FRANCE; HEART INFARCTION; HEMOSTASIS; HUMAN; INCIDENCE; INTENSIVE CARE; MEDICAL SOCIETY; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECEPTOR BINDING; RISK ASSESSMENT; SURGERY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; ANESTHESIA; CARDIOLOGY; CHEMICALLY INDUCED DISORDER; NEUROLOGY; PEROPERATIVE COMPLICATION;

ANESTHESIA; CARDIOLOGY; HUMAN; INTENSIVE CARE; INTRAOPERATIVE COMPLICATIONS; NEUROLOGY; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; HUMANS;

EID: 0036627885     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rules of evidence and clinical recommendations on the used of antithrombotic agents
2. Platelet-active drugs: The relationships among dose, effectiveness, and side effects
3. Platelet function inhibitors in the Year 2000
4. Platelet GPIIb-IIIa blockers
5. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in aspirin stent international cooperative study (CLASSICS)
6. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
7. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke
8. European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
9. Prevention of venous thromboembolism
10. Collaborative overview of randomised trials of antiplatelet therapy-III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet trialists' collaboration
11. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial
12. A critical reappraisal of the bleeding time
13. A study of platelet functions with a new analyzer using high shear stress (PFA 100) in patients undergoing coronary artery bypass graft
14. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultrega) multicenter study
15. Aspirin usage and perioperative blood loss in patients undergoing unexpected operations
16. Increased blood loss after preoperative NSAID. Retrospective study of 186 hip arthroplasties
17. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
18. Antiplatelet therapy and cataract surgery
19. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators
20. Risk factors for postcarotid endarterectomy hematoma formation
21. Do antiplatelet agents contribute to the development of perioperative spinal hematoma?
22. CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre- eclampsia among 9364 pregnant women
23. Reduction of post-operative mortality and morbidity with epidural or spinal anaesthesia: Results from overview of randomised trials
24. Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated with regional anesthesia
25. Antithrombotic therapy in peripheral arterial occlusive disease
26. Myocardial infarction after aspirin cessation in stable coronary artery disease patients
27. Perioperative activation of hemostasis in vascular surgery patients
28. Catastrophic outcomes of noncardiac surgery soon after coronary stenting
29. Médicaments inhibiteurs des fonctions plaquettaires
30. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial
31. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations
32. Tranexamic acid administration after cardiac surgery: A prospective, randomized, double-blind, placebo-controlled study
33. Drugs to minimize perioperative blood loss in cardiac surgery: Meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators
34. Analyses of coronary graft patency after aprotinine use: Results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial
35. Desmopressin effect on acetylsalicylic acid impaired platelet function